{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:15:16Z","timestamp":1792077316448,"version":"4.4.0"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.3816","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T15:31:43Z","timestamp":1617204703000},"page":"e213816","source":"Crossref","is-referenced-by-count":3,"title":["Quantifying the Costs of Care Among Patients With High-Risk Non\u2013Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration"],"prefix":"10.1001","volume":"4","author":[{"given":"Alejandro","family":"Sanchez","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"2","key":"zic210040r1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease.","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"zic210040r2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non\u2013muscle invasive bladder cancer: AUA\/SUO guideline.","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"10","key":"zic210040r3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non\u2013muscle-invasive bladder cancer: an analysis based on risk categories.","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"issue":"1","key":"zic210040r4","doi-asserted-by":"publisher","first-page":"76.e1","DOI":"10.1016\/j.urolonc.2020.09.030","article-title":"A national cross-sectional survey of financial toxicity among bladder cancer patients.","volume":"39","author":"Ehlers","year":"2021","journal-title":"Urol Oncol"},{"issue":"3","key":"zic210040r5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin in the Veterans Affairs Health System.","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1-2","key":"zic210040r6","first-page":"276","article-title":"The management of newly-diagnosed non\u2013muscle invasive bladder cancer in Veterans Integrated Services Network 02 of the Veterans Health Administration.","volume":"185","author":"Caputo","year":"2020","journal-title":"Mil Med"},{"issue":"6","key":"zic210040r7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/bju.2013.112.issue-6","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS).","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"zic210040r8","article-title":"Pembrolizumab for non\u2013muscle-invasive bladder cancer\u2014a costly therapy in search of evidence.","author":"Gill","journal-title":"JAMA Oncol"},{"issue":"1","key":"zic210040r9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non\u2013muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2777983\/sanchez_2021_ic_210040_1616524211.57763.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T21:34:31Z","timestamp":1619818471000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2777983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3816","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]}}}